Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Jiangsu HengRui Medicine Co., Ltd.
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Taiho Oncology, Inc.
NRG Oncology
Merck Sharp & Dohme LLC
PrECOG, LLC.
Eli Lilly and Company
Eli Lilly and Company
Gilead Sciences
AstraZeneca
Revolution Medicines, Inc.
Pfizer
University Medical Center Groningen
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Mirati Therapeutics Inc.
Centre Leon Berard
Sichuan University
Nanfang Hospital, Southern Medical University